2021
DOI: 10.1016/j.transci.2021.103188
|View full text |Cite
|
Sign up to set email alerts
|

Ubiquitous convalescent plasma: An artificial universal plasma for COVID-19 patients

Abstract: Objectives and background: In December 2019, the first case of COVID-19 was reported in Wuhan, China. Its causative virus, is a novel strain of RNA viruses with high mortality rate. There is no definitive treatment, but among available approaches the use of recovered patients' plasma containing specific antibodies can enhance the immune response against coronavirus. However, the dearth of eligible donors and also ABO incompatibility in plasma transfusion, have limited this therapeutic method. Therefore, it is … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 25 publications
0
1
0
Order By: Relevance
“…It is difficult to establish these procedures in small individual blood banks as they require either specialized or large-scale equipment. The principle of adsorbing the isoagglutinins onto structures expressing the cognate antigens can also be applied by adding red cells from red cell concentrates [ 17 ]. This also allows for the removal of the formed immune complexes.…”
Section: Introductionmentioning
confidence: 99%
“…It is difficult to establish these procedures in small individual blood banks as they require either specialized or large-scale equipment. The principle of adsorbing the isoagglutinins onto structures expressing the cognate antigens can also be applied by adding red cells from red cell concentrates [ 17 ]. This also allows for the removal of the formed immune complexes.…”
Section: Introductionmentioning
confidence: 99%